Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib [MK0966] in Decreasing the Risk of Prostate Cancer (ViP Study).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Rofecoxib (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 23 Aug 2008 New trial record.